JP7503561B2 - 新規ジペプチド化合物及びその使用方法 - Google Patents

新規ジペプチド化合物及びその使用方法 Download PDF

Info

Publication number
JP7503561B2
JP7503561B2 JP2021547662A JP2021547662A JP7503561B2 JP 7503561 B2 JP7503561 B2 JP 7503561B2 JP 2021547662 A JP2021547662 A JP 2021547662A JP 2021547662 A JP2021547662 A JP 2021547662A JP 7503561 B2 JP7503561 B2 JP 7503561B2
Authority
JP
Japan
Prior art keywords
optionally substituted
compound
pharma
acceptable salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021547662A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509366A5 (https=
JP2022509366A (ja
Inventor
ミン リ
ユ ファン
Original Assignee
ファーハイ ユーエス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーハイ ユーエス インコーポレイテッド filed Critical ファーハイ ユーエス インコーポレイテッド
Publication of JP2022509366A publication Critical patent/JP2022509366A/ja
Publication of JP2022509366A5 publication Critical patent/JP2022509366A5/ja
Application granted granted Critical
Publication of JP7503561B2 publication Critical patent/JP7503561B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2021547662A 2018-10-29 2019-10-25 新規ジペプチド化合物及びその使用方法 Active JP7503561B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862751984P 2018-10-29 2018-10-29
US62/751,984 2018-10-29
PCT/US2019/057985 WO2020092139A1 (en) 2018-10-29 2019-10-25 Novel dipeptide compounds and uses thereof

Publications (3)

Publication Number Publication Date
JP2022509366A JP2022509366A (ja) 2022-01-20
JP2022509366A5 JP2022509366A5 (https=) 2022-10-20
JP7503561B2 true JP7503561B2 (ja) 2024-06-20

Family

ID=70464360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547662A Active JP7503561B2 (ja) 2018-10-29 2019-10-25 新規ジペプチド化合物及びその使用方法

Country Status (10)

Country Link
US (1) US12209141B2 (https=)
EP (1) EP3873916B8 (https=)
JP (1) JP7503561B2 (https=)
KR (1) KR102882178B1 (https=)
CN (2) CN116813691B (https=)
AU (1) AU2019371209B2 (https=)
CA (1) CA3117599A1 (https=)
IL (1) IL282676B1 (https=)
TW (1) TWI870362B (https=)
WO (1) WO2020092139A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3117599A1 (en) * 2018-10-29 2020-05-07 Huahai Us Inc. Novel dipeptide compounds and uses thereof
CN118496301A (zh) * 2023-02-16 2024-08-16 丽珠医药集团股份有限公司 一种二肽类化合物的盐、其制备方法和用途
WO2024169765A1 (zh) * 2023-02-16 2024-08-22 上海华汇拓医药科技有限公司 一种二肽类化合物的盐、其制备方法和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000344745A (ja) 1999-05-03 2000-12-12 Adir 新規２，３−メタノ−アミノ酸化合物、それらの製造方法、及びそれらを含有する医薬組成物
US20020169113A1 (en) 2001-03-19 2002-11-14 Koo Lee Orally available peptidic thrombin inhibitors
JP2005517734A (ja) 2002-02-21 2005-06-16 レ ラボラトワール セルヴィエ 新規なアミノ酸誘導体、その製造方法及び該誘導体を含む薬剤組成物
JP2006249098A (ja) 1994-01-27 2006-09-21 Mitsubishi Chemicals Corp プロリンアミド誘導体
JP2013543850A (ja) 2010-11-08 2013-12-09 上海医薬工業研究院 新規な化合物、その製造方法および用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
MX9201416A (es) * 1991-03-28 1992-10-01 Rhone Poulenc Rorer Int Peptidos y pseudopeptidos antitromboticos.
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10339862A1 (de) 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
EP1778616A1 (en) * 2004-08-09 2007-05-02 Cancer Research Technology Limited Alpha-ketoglutarates and their use as therapeutic agents
DE102004062864A1 (de) 2004-12-21 2006-06-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Folienbehälter
CN100502914C (zh) * 2005-10-24 2009-06-24 丽珠医药集团股份有限公司 一种治疗脑中风的中药组合物及其制备方法
MX2008012574A (es) * 2006-03-29 2008-10-10 Schering Corp Derivados de himbacina monociclitos y biciclicos utiles como antagonistas del receptor de trombina.
CN101784516B (zh) * 2007-06-13 2014-07-02 百时美施贵宝公司 作为凝血因子抑制剂的二肽类似物
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante
CN102796168B (zh) * 2011-05-27 2014-02-26 首都医科大学 一种具有溶血栓活性的化合物，及其制备方法和应用
CN103833827B (zh) * 2012-11-27 2016-08-03 上海医药工业研究院 一种酰胺类化合物、其药物组合物、制备方法及应用
AU2014278172B2 (en) * 2013-06-12 2018-08-09 Mycovia Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN106316975A (zh) * 2015-06-15 2017-01-11 山东轩竹医药科技有限公司 酰胺类化合物及其作为tgr5激动剂的应用
CA3117599A1 (en) * 2018-10-29 2020-05-07 Huahai Us Inc. Novel dipeptide compounds and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006249098A (ja) 1994-01-27 2006-09-21 Mitsubishi Chemicals Corp プロリンアミド誘導体
JP2000344745A (ja) 1999-05-03 2000-12-12 Adir 新規２，３−メタノ−アミノ酸化合物、それらの製造方法、及びそれらを含有する医薬組成物
US20020169113A1 (en) 2001-03-19 2002-11-14 Koo Lee Orally available peptidic thrombin inhibitors
JP2005517734A (ja) 2002-02-21 2005-06-16 レ ラボラトワール セルヴィエ 新規なアミノ酸誘導体、その製造方法及び該誘導体を含む薬剤組成物
JP2013543850A (ja) 2010-11-08 2013-12-09 上海医薬工業研究院 新規な化合物、その製造方法および用途

Also Published As

Publication number Publication date
JP2022509366A (ja) 2022-01-20
KR102882178B1 (ko) 2025-11-05
IL282676A (en) 2021-06-30
US12209141B2 (en) 2025-01-28
CN113195515A (zh) 2021-07-30
EP3873916C0 (en) 2025-02-19
US20210395299A1 (en) 2021-12-23
CA3117599A1 (en) 2020-05-07
AU2019371209B2 (en) 2025-05-01
EP3873916A1 (en) 2021-09-08
EP3873916B8 (en) 2025-03-26
IL282676B1 (en) 2026-03-01
CN116813691A (zh) 2023-09-29
EP3873916A4 (en) 2022-08-10
AU2019371209A1 (en) 2021-05-27
KR20210086682A (ko) 2021-07-08
TW202031674A (zh) 2020-09-01
EP3873916B1 (en) 2025-02-19
TWI870362B (zh) 2025-01-21
CN113195515B (zh) 2024-11-15
CN116813691B (zh) 2024-04-12
WO2020092139A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
JP5662980B2 (ja) Ｎ−（５−クロロ−２−ピリジニル）−２−［［４−［（ジメチルアミノ）イミノメチル］ベンゾイル］アミノ］−５−メトキシ−ベンズアミド、第Ｘａ因子阻害剤の薬学的な塩および多形体
JP6154473B2 (ja) 第ＸＩａ因子阻害剤の結晶形
WO2011118672A1 (ja) 血漿カリクレイン阻害剤
CN107428723B (zh) 生长素释放肽o-酰基转移酶抑制剂
JP7503561B2 (ja) 新規ジペプチド化合物及びその使用方法
JP2009040777A (ja) プラスミノーゲンアクチベーターインヒビター−１阻害剤
EP1371646B1 (en) Aryl-substituted alicyclic compound and medical composition comprising the same
JPWO2003011812A1 (ja) ヒト−β−トリプターゼ阻害活性を有する新規アミン誘導体およびそれを含有する医薬
CN101421242B (zh) 二酰胺衍生物
KR20020062312A (ko) １,３,４-옥사디아졸린 유도체 및 이들을 유효 성분으로하는 약제
CN108558760B (zh) 一类芳香酰胺化合物及其制备方法和用途
HK40094572A (zh) 新的二肽类化合物及其用途
HK40094572B (zh) 新的二肽类化合物及其用途
US20250179118A1 (en) Novel dipeptide compounds and uses thereof
HK40060683A (en) Novel dipeptide compounds and uses thereof
HK40060683B (en) Novel dipeptide compounds and uses thereof
JP2001524522A (ja) トロンビン阻害剤
JP2001114699A (ja) キマーゼ阻害作用を有する化合物を有効成分とする血管新生阻害剤
JP2011073993A (ja) 抗凝固作用を有するキノキサリンカルボキサミド誘導体
HK1212333B (en) Crystalline forms of a factor xia inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230828

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231124

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240222

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240411

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240509

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240610

R150 Certificate of patent or registration of utility model

Ref document number: 7503561

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350